Sharescart Research Club logo

Key Financials Snapshot

TTM · Consolidated · ₹ in Cr
Market Cap
₹28466 Cr.
Stock P/E
58.6
P/B
10.2
Current Price
₹1659.1
Book Value
₹ 163.2
Face Value
1
52W High
₹1875.3
52W Low
₹ 1262.4
Dividend Yield
0%

Inventurus Knowledge Overview

Business

Inventurus Knowledge Solutions Ltd. (IKS) is an India-based company primarily engaged in providing Business Process Management (BPM) and IT solutions, with a strong focus on the healthcare sector. Its core business model revolves around offering services, particularly Revenue Cycle Management (RCM), medical coding, medical billing, and other administrative and IT support services, predominantly to healthcare providers in the United States. The company makes money by charging fees for these outsourced services, which can be based on transaction volumes, a percentage of collections, or a retainer model, helping clients improve operational efficiency, reduce costs, and optimize revenue generation.

Revenue Mix

IKS's revenue is largely dominated by its healthcare-focused services. The primary segment is healthcare Revenue Cycle Management (RCM), which encompasses a suite of services from patient registration to final claim settlement. Within RCM, specific services would include medical coding, medical billing, accounts receivable follow-up, denial management, and payment posting. While specific percentage contributions are not publicly available, the vast majority of its revenue is derived from providing these specialized back-office and IT-enabled services to the US healthcare industry.

Industry

IKS operates in the highly competitive global IT-BPM industry, specifically within the healthcare vertical. The industry structure is characterized by a mix of large, diversified IT service providers with healthcare practices and niche, specialized healthcare BPO firms. The demand for outsourcing in healthcare is driven by increasing cost pressures, regulatory complexities (like HIPAA), and the need for operational efficiency among healthcare providers. IKS positions itself as a specialist in US healthcare RCM, leveraging deep domain expertise and a global delivery model (offshore in India for US clients). It competes with both large Indian IT service companies having healthcare segments and other pure-play healthcare RCM providers.

MOAT

IKS's primary competitive advantages include:

Domain Expertise: Deep understanding of the complex US healthcare regulatory environment, medical coding standards, and billing processes. This specialized knowledge is critical and difficult for generalist firms to replicate quickly.

Switching Costs: Once a healthcare provider integrates IKS's RCM services into its operations, the costs and disruption associated with switching to a new vendor (data migration, process re-engineering, staff training) are high, creating customer stickiness.

Operational Scale & Efficiency: Ability to process large volumes of transactions efficiently due to optimized workflows and potentially proprietary platforms, leading to cost advantages for clients.

Growth Drivers

Key factors that can drive IKS's growth over the next 3-5 years include:

Increasing Outsourcing Trend: Continued pressure on US healthcare providers to reduce costs and improve efficiency will drive further outsourcing of non-core functions like RCM.

Complexity of US Healthcare: Ever-evolving regulatory landscape and payment models in the US healthcare system necessitates specialized expertise that IKS provides.

Digital Transformation: Adoption of automation, AI, and analytics in RCM and other healthcare processes will create new service opportunities.

Aging Population & Healthcare Demand: An increasing aging population in the US implies higher healthcare utilization, leading to more RCM activity.

Service Expansion: Potential to expand into new adjacent healthcare IT/BPO services or deepen existing offerings with advanced analytics and AI.

Risks

Key business risks for IKS include:

US Healthcare Policy Changes: Any significant shifts in US healthcare regulations, reimbursement models (e.g., from fee-for-service to value-based care), or government spending could adversely impact demand for RCM services.

Intense Competition & Pricing Pressure: The IT-BPM sector is highly competitive, potentially leading to pricing pressures and margin erosion.

Client Concentration: Reliance on a few large clients could expose the company to significant revenue volatility if a major client is lost or scales down operations.

Talent Acquisition & Retention: Difficulty in attracting, training, and retaining skilled professionals (e.g., medical coders, IT specialists) is a constant challenge.

Data Security & Compliance: Handling sensitive patient health information (PHI) requires strict adherence to HIPAA and other data privacy regulations. Any breach or non-compliance could lead to severe penalties and reputational damage.

Technological Disruption: Rapid advancements in automation and AI could disrupt traditional BPO models, requiring continuous investment in new technologies.

Management & Ownership

As a listed Indian company, IKS typically has a promoter-driven management structure, where the founding family or individuals hold a significant ownership stake and play a crucial role in strategic direction. The management team likely possesses deep operational and domain expertise within the healthcare IT-BPM space, which is essential for navigating this specialized niche. Ownership is typically a mix of promoter holdings, institutional investors (both domestic and foreign), and public shareholders. Specific details on promoter names or their exact stake are not part of this general overview.

Outlook

IKS is strategically positioned in the resilient and growing healthcare IT-BPM sector, benefiting from the ongoing need for cost efficiency and specialized expertise among US healthcare providers. The company's deep domain knowledge in Revenue Cycle Management provides a strong foundation. The bull case hinges on continued expansion of outsourcing by healthcare organizations, successful adoption of new technologies like AI in RCM, and efficient execution in a competitive landscape. However, the bear case must consider the significant risks posed by potential changes in US healthcare policy, intense pricing competition, and the constant need to innovate and secure sensitive data. The company's future performance will depend on its ability to leverage its specialized expertise, adapt to technological shifts, and navigate the complex regulatory environment of the US healthcare market while maintaining client relationships.

Inventurus Knowledge Share Price

Live · BSE / NSE · Inception: 2006
| |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Consolidated · annual

Inventurus Knowledge Quarterly Results

#(Fig in Cr.) Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Net Sales 567 620 640 643 657 724 740 781 815 858
Other Income 6 15 4 5 27 3 3 4 6 5
Total Income 573 635 644 648 684 727 743 785 821 863
Total Expenditure 405 494 467 454 476 498 502 509 533 557
Operating Profit 168 140 177 194 208 229 241 275 287 305
Interest 26 32 26 22 21 21 18 16 23 13
Depreciation 19 27 28 28 28 28 28 30 32 34
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 124 81 122 144 160 180 195 229 232 258
Provision for Tax 22 17 27 31 30 32 43 47 46 47
Profit After Tax 102 64 95 113 130 148 152 182 186 211
Adjustments 0 0 0 0 0 0 0 -1 -2 -5
Profit After Adjustments 102 64 95 113 130 148 152 181 183 206
Adjusted Earnings Per Share 6 3.8 5.6 6.7 7.6 8.7 8.8 10.6 10.7 12.1

Inventurus Knowledge Profit & Loss

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 191 291 351 397 503 529 553 764 1031 1818 2664 3194
Other Income 0 1 3 12 23 32 16 21 29 40 40 18
Total Income 191 292 354 409 527 561 569 784 1060 1858 2704 3212
Total Expenditure 164 232 305 352 393 368 348 466 639 1297 1894 2101
Operating Profit 27 60 49 57 134 192 221 319 421 561 810 1108
Interest 9 9 7 6 5 7 8 7 6 61 91 70
Depreciation 6 10 16 28 33 41 30 23 25 59 113 124
Exceptional Income / Expenses 0 0 0 0 0 0 0 -20 -31 0 0 0
Profit Before Tax 13 41 26 22 97 145 183 269 359 442 606 914
Provision for Tax 2 2 3 4 4 7 17 36 54 71 120 183
Profit After Tax 11 39 23 18 93 137 165 233 305 370 486 731
Adjustments -0 -0 -0 0 0 0 0 0 0 0 0 -8
Profit After Adjustments 11 39 23 18 93 137 165 233 305 370 486 722
Adjusted Earnings Per Share 0.7 2.4 1.4 1.1 5.8 8.4 10.1 13.7 18.1 21.9 28.6 42.2

Inventurus Knowledge Balance Sheet

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds -17 25 54 82 200 283 457 647 829 1158 1790
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 37 56 23 10 1 0 0 0 0 812 509
Other Non-Current Liabilities 1 2 4 -2 -11 22 9 -19 -50 92 86
Total Current Liabilities 59 67 80 90 50 81 59 83 115 881 651
Total Liabilities 80 150 161 181 240 386 524 711 894 2943 3036
Fixed Assets 17 34 43 80 52 98 87 76 59 1833 1790
Other Non-Current Assets 20 43 61 12 12 55 93 174 137 213 462
Total Current Assets 44 73 56 88 175 233 345 461 698 898 784
Total Assets 80 150 161 181 240 386 524 711 894 2943 3036

Inventurus Knowledge Cash Flow

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 2 3 15 6 6 38 82 53 146 124 -23
Cash Flow from Operating Activities 18 53 45 45 97 163 175 233 288 210 318
Cash Flow from Investing Activities -22 -39 -35 -29 -13 -80 -166 -82 -156 -1141 244
Cash Flow from Financing Activities 5 -2 -18 -16 -52 -41 -37 -59 -152 780 -389
Net Cash Inflow / Outflow 1 12 -9 -0 32 42 -27 92 -20 -151 173
Closing Cash & Cash Equivalent 3 15 6 6 38 82 53 146 124 -23 146

Inventurus Knowledge Ratios

# Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 0.68 2.39 1.4 1.15 5.77 8.45 10.1 13.72 18.13 21.9 28.55
CEPS(Rs) 1.06 3.02 2.38 2.9 7.81 10.94 11.95 15.1 19.59 25.35 35.17
DPS(Rs) 0 0 0 0 0 1.19 1.19 5.4 10 10 0
Book NAV/Share(Rs) -1.09 1.55 3.27 4.94 11.82 16.91 27.35 37.66 48.94 67.66 102.96
Core EBITDA Margin(%) 14.01 20.27 13.11 11.29 22.01 30.35 37.01 39.01 38.01 28.67 28.91
EBIT Margin(%) 11.06 16.97 9.29 7.2 20.15 28.72 34.45 36.1 35.43 27.66 26.19
Pre Tax Margin(%) 6.54 14 7.42 5.57 19.24 27.35 33.06 35.16 34.84 24.3 22.76
PAT Margin (%) 5.6 13.43 6.65 4.65 18.51 25.99 29.93 30.51 29.6 20.38 18.25
Cash Profit Margin (%) 8.66 17 11.3 11.74 25.04 33.64 35.42 33.56 31.98 23.6 22.47
ROA(%) 13.31 33.91 15 10.79 44.24 43.89 36.34 37.73 38.06 19.31 16.26
ROE(%) 0 929.34 58.45 27.57 68.97 59.01 45.74 42.85 41.72 37.63 33.55
ROCE(%) 36.17 60.44 29.33 22.73 60.07 62.42 51.44 49.95 49.52 31.77 28.65
Receivable days 71.51 53.27 46 45.45 44.61 48.18 49.37 40.74 45.34 52.46 61.24
Inventory Days 0 0 0 0 0 0 0 0 0 0.15 0
Payable days 0 0 0 0 0 0 0 0 0 0 0
PER(x) 0 0 0 0 0 0 0 0 0 0 53.41
Price/Book(x) 0 0 0 0 0 0 0 0 0 0 14.81
Dividend Yield(%) 0 0 0 0 0 0 0 0 0 0 0
EV/Net Sales(x) 0.42 0.25 0.19 0.14 -0.07 -0.22 -0.39 -0.43 -0.49 0.48 9.95
EV/Core EBITDA(x) 2.96 1.22 1.33 0.96 -0.25 -0.59 -0.98 -1.04 -1.2 1.54 32.71
Net Sales Growth(%) 0 52.33 20.41 13.08 26.91 5.08 4.45 38.2 35.05 76.28 46.54
EBIT Growth(%) 0 133.61 -34.09 -12.34 255.11 49.8 25.28 44.82 32.55 37.59 38.78
PAT Growth(%) 0 265.06 -40.33 -20.98 405.05 47.55 20.31 40.87 31.02 21.38 31.2
EPS Growth(%) 0 248.98 -41.29 -18.12 403.05 46.35 19.5 35.92 32.1 20.77 30.41
Debt/Equity(x) -4.41 3.13 1.15 0.66 0.02 0 0 0 0 1.03 0.42
Current Ratio(x) 0.74 1.09 0.7 0.98 3.52 2.88 5.86 5.56 6.07 1.02 1.2
Quick Ratio(x) 0.74 1.09 0.7 0.98 3.52 2.88 5.86 5.56 6.07 1.02 1.2
Interest Cover(x) 2.45 5.72 4.98 4.42 22.22 20.97 24.78 38.54 60.37 8.23 7.63
Total Debt/Mcap(x) 0 0 0 0 0 0 0 0 0 0 0.03

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR +47% +52% +38% +30%
Operating Profit CAGR +44% +36% +33% +41%
PAT CAGR +31% +28% +29% +46%
Share Price CAGR +4%
ROE Average +34% +38% +40% +122%
ROCE Average +29% +37% +42% +44%

Inventurus Knowledge Shareholding Pattern

Latest · Mar 2026
100% held
Promoters 63.72 %
FII 8.19 %
DII (MF + Insurance) 6.4 %
Public (retail) 36.28 %
# Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Promoter 63.7263.7263.7263.7263.7263.72
FII 5.475.376.57.027.568.19
DII 4.424.044.334.896.066.4
Public 36.2836.2836.2836.2836.2836.28
Others 000000
Total 100100100100100100

Inventurus Knowledge Peer Comparison

IT - Software Edit Columns

Inventurus Knowledge Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

Inventurus Knowledge Pros & Cons

Pros

  • Company has delivered good profit growth of 28% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 38%
  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend.
  • Stock is trading at 10.2 times its book value.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp